Consultation outcome

Classification of Nexium Control 20mg Gastro-Resistant

From:
Medicines and Healthcare products Regulatory Agency
Published
2 July 2014
Last updated
27 January 2015 — See all updates
This consultation has concluded

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Nexium Control from a pharmacy (P) medicine to a general sales list medicine (GSL) in the UK for the short-term treatment of reflux symptoms (eg heartburn and acid regurgitation) in adults.

See the public assessment report for more information.

Detail of feedback received

A total of 10 responses were received, of which 2 were in favour, 4 raised issues and 4 were not in favour. Two of the responses were confidential.

See all the reponses to this consultation.

Original consultation

Summary

This consultation (ARM88) welcomes views on proposals to classify Nexium Control 20mg Gastro-Resistant Tablets as a general sales list (GSL) product in the UK.

This consultation ran from
to

Consultation description

MHRA is asking for feedback on proposals to classify Nexium Control 20mg Gastro-Resistant tablets as a general sales list (GSL) product in the UK. The GSL classification summary and label and patient information leaflet as provided by the company are included in this document.

Documents

Consultation document, ARM88 - Nexium Control 20mg Gastro-Resistant Tablets - request to classify as GSL

PDF, 3.5 MB, 18 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Published 2 July 2014
Last updated 27 January 2015 + show all updates

  1. The responses to and outcome of this consultation have been published.

  2. First published.